Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
  1. Home
  3. Diagnostic And Prognostic Value Of Hsa_pir_022710, Hsa_pir_019822, And Hsa_pir_020840 In Early-stage Non-small-cell Lung Cancer: Implications For Recurrence And Survival In Squamous Cell Carcinoma Patients.
  1. Home
  3. Diagnostic And Prognostic Value Of Hsa_pir_022710, Hsa_pir_019822, And Hsa_pir_020840 In Early-stage Non-small-cell Lung Cancer: Implications For Recurrence And Survival In Squamous Cell Carcinoma Patients.

Related Experiment Video

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

353

Diagnostic and Prognostic Value of hsa_piR_022710, hsa_piR_019822, and hsa_piR_020840 in Early-Stage Non-Small-Cell

Yangyi He1,2, Antonio Altuna-Coy1, Melissa Acosta-Plasencia1

  • 1Molecular Oncology and Embryology Laboratory, Human Anatomy and Embryology Unit, Department of Surgery and Medical-Surgical Specialties, Faculty of Medicine and Health Sciences, Universitat de Barcelona (UB), c. Casanova 143, 08036 Barcelona, Spain.

International Journal of Molecular Sciences
|April 17, 2025

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
NSCLCbiomarkerspiRNAprognosisrecurrencesquamous cell carcinoma

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K

Related Experiment Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

353
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K

High levels of specific PIWI-interacting RNAs (piRNAs) correlate with increased recurrence risk and poorer survival in non-small-cell lung cancer (NSCLC), particularly in squamous cell carcinoma. These piRNAs may guide personalized treatment strategies for NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small-cell lung cancer (NSCLC) is a leading cause of cancer mortality, with recurrence after surgery being a primary concern for early-stage patients.
  • Novel diagnostic and prognostic biomarkers are urgently needed for NSCLC management.
  • PIWI-interacting RNAs (piRNAs) are small RNAs involved in genomic stability and epigenetics, with some implicated in cancer deregulation.

Purpose of the Study:

  • To investigate the expression of specific piRNAs (hsa_piR_022710, hsa_piR_019822, hsa_piR_020840) in NSCLC.
  • To develop predictive models for recurrence risk, overall survival (OS), and disease-free survival (DFS) using these piRNAs.
  • To explore the potential of piRNAs as biomarkers for NSCLC prognosis and personalized treatment.

Main Methods:

  • Quantitative reverse transcription PCR (RT-qPCR) was used to measure piRNA expression in 277 NSCLC patients.
  • Survival and Classification and Regression Tree (CART) models were developed to analyze the association between piRNA levels and patient outcomes.
  • Tissue samples were analyzed to differentiate between tumor and normal tissues, and between adenocarcinoma and squamous cell carcinoma (LUSC).

Main Results:

  • hsa_piR_019822 and hsa_piR_020840 differentiated tumor from normal tissue and between adenocarcinoma and LUSC.
  • Elevated hsa_piR_019822 and hsa_piR_022710 expression correlated with higher recurrence risk and poorer DFS and OS in LUSC patients.
  • Patients with high hsa_piR_022710 expression showed greater benefit from adjuvant treatment.

Conclusions:

  • Higher piRNA levels are associated with increased recurrence risk and worse survival outcomes in NSCLC, particularly in LUSC.
  • Specific piRNAs (hsa_piR_019822, hsa_piR_022710, hsa_piR_020840) show potential as diagnostic and prognostic biomarkers for NSCLC.
  • PiRNA expression may inform personalized treatment strategies for LUSC patients, including adjuvant therapy selection.